ArticleTranslational cancer research2025
Impact of single-site distant metastases on prognosis in advanced ovarian cancer: a Surveillance, Epidemiology, and End Results population-based study.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Late-stage distant metastasis is the primary cause of death and poor prognosis in patients with ovarian cancer. This study aims to evaluate the association between patterns of single distant metastases and survivals in advanced ovarian cancer, and to identify the prognostic factors for site-specific distant metastases. Methods: Data collected between 2010 and 2016 were obtained from the Surveillance, Epidemiology, and End Results (SEER) database. Kaplan-Meier survival curves and Cox regression were used to analyze overall survival (OS) and disease-specific survival (DSS). Subgroup and interaction analyses were performed to assess the effects on survival and prognosis. Floating absolute risk (FAR) methods and propensity score matching (PSM) analyses were used to reduce confounding bias. Results: A total of 639 patients were included in this study. The most prevalent single distant metastatic site was the liver (n=338; 52.9%), followed by the lungs (n=267; 41.8%), bones (n=29; 4.5%), and brain (n=5; 0.8%), with median survival times of 31, 25, 25, and 19 months, respectively. Through univariate and multifactorial analyses, we found that serous cancer, surgery, chemotherapy, and liver metastasis were independent factors influencing the prognosis of ovarian cancer. Compared to other metastatic sites, patients with liver metastasis exhibited significantly better OS [hazard ratio (HR) =0.79, 95% confidence interval (CI): 0.64-0.98, P=0.03], which remained consistent even after the application of FAR (HR =0.79, 95% CI: 0.62-1.02, P=0.03) and PSM (HR =0.77, 95% CI: 0.62-0.96, P=0.02). Similar results were observed in the DSS. Additionally, subgroup analysis and interaction tests revealed a significant interaction between the serous histological type and liver metastasis (P=0.007). Conclusions: Among patients with single-site distant metastasis of advanced ovarian cancer, the prognosis varies significantly depending on the specific metastatic site. Liver metastasis is associated with better outcomes, providing new evidence for clinical diagnosis and individualized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.